Effects and mechanisms of resveratrol on the amelioration of oxidative stress and hepatic steatosis in KKAy mice

Nutrition & Metabolism

Xiang Feng¹  Wenhua Ling¹  Zili Zhang¹  Yanshuang Sun¹  Wenxue Li²  Xiaohong Zhao⁴  Zilun Li³  Sifan Chen²  Wei Zhu² 

[1] Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou, Guangdong, People’s Republic of China;Guangzhou Center for Disease Control and Prevention, Guangzhou, Guangdong, People’s Republic of China;Division of Vascular Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People’s Republic of China;Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People’s Republic of China

关键词: AMPK;    Sirt1;    Resveratrol;    Oxidative stress;    Lipid metabolic disorder;    NAFLD;   

Others  :  1131756
DOI  :  10.1186/1743-7075-11-35

 received in 2014-03-23, accepted in 2014-08-06,  发布年份 2014

【 摘 要 】

Background

The exact mechanism of the protective role of Resveratrol (Res) in lipid metabolism and oxidative stress is not well elucidated. The present study aimed to investigate the potential benefits and possible mechanisms of Res on the amelioration of oxidative stress and hepatic steatosis in a KKAy mouse model.

Methods

A total of 30 KKAy male mice were randomly divided into three groups: a normal chow group, a low resveratrol group and a high resveratrol group. After a 12-wk study period, serum levels of TG, TC, LDL-C and HDL-C, the liver content of TG and TC, ROS, GSH, GPx, SOD and MDA levels were measured. Ectopic lipid deposition was observed in sectioned frozen liver tissues. The mRNA levels of ATGL and HSL in the liver tissues were determined via real-time PCR. Furthermore, the protein expression of p47phox, gp91phox, ATGL, HSL, Sirt1, AMPK and FOXO1 were analyzed using western blotting.

Results

Following Res supplementation, serum levels of TG and MDA were decreased, while the HDL-C and SOD levels were increased in KKAy mice. Furthermore, Res treatment increased GSH and GPx in liver tissues, while it decreased ROS. In addition, Res significantly reduced hepatic steatosis. After Res treatment, concentrations of p47phox (membrane) and gp91phox proteins were reduced, while p-HSL, HSL and ATGL protein expression levels were increased. Mechanistically, the levels of Sirt1, p-AMPK and p-FOXO1 expression in the liver tissues were up-regulated following supplementation with Res, and FOXO1 protein was released from the nucleus into the cytoplasm.

Conclusions

Res is able to attenuate hepatic steatosis and lipid metabolic disorder and enhance the antioxidant ability in KKAy mice, possibly by up-regulating Sirt1 expression and the phosphorylation of AMPK.

【 授权许可】

   
2014 Zhu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231.
• [2]Cohen JC, Horton JD, Hobbs HH: Human fatty liver disease: old questions and new insights. Science 2011, 332:1519-1523.
• [3]Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ: Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005, 115:1343-1351.
• [4]Reid BN, Ables GP, Otlivanchik OA, Schoiswohl G, Zechner R, Blaner WS, Goldberg IJ, Schwabe RF, Chua SC Jr, Huang LS: Hepatic overexpression of hormone-sensitive lipase and adipose triglyceride lipase promotes fatty acid oxidation, stimulates direct release of free fatty acids, and ameliorates steatosis. J Biol Chem 2008, 283:13087-13099.
• [5]Pervaiz S: Resveratrol: from grapevines to mammalian biology. FASEB J 2003, 17:1975-1985.
• [6]Thirunavukkarasu M, Penumathsa SV, Koneru S, Juhasz B, Zhan L, Otani H, Bagchi D, Das DK, Maulik N: Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med 2007, 43:720-729.
• [7]Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA: Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
• [8]Masubuchi Y, Sugiyama S, Horie T: Th1/Th2 cytokine balance as a determinant of acetaminophen-induced liver injury. Chem Biol Interact 2009, 179:273-279.
• [9]Sun C, Zhang F, Ge X, Yan T, Chen X, Shi X, Zhai Q: Sirt1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab 2007, 6:307-319.
• [10]Long YC, Zierath JR: AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 2006, 116:1776-1783.
• [11]Fillmore N, Jacobs DL, Mills DB, Winder WW, Hancock CR: Chronic AMP-activated protein kinase activation and a high-fat diet have an additive effect on mitochondria in rat skeletal muscle. J Appl Physiol 2010, 109:511-520.
• [12]Cantó C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, Elliott PJ, Puigserver P, Auwerx J: AMPK regulates energy expenditure by modulating NAD+ metabolism and Sirt1 activity. Nature 2009, 458:1056-1060.
• [13]Lan F, Cacicedo JM, Ruderman N, Ido Y: Sirt1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J Biol Chem 2008, 283:27628-27635.
• [14]Castle CK, Colca JR, Melchior GW: Lipoprotein profile characterization of the KKA(y) mouse, a rodent model of type II diabetes, before and after treatment with the insulin-sensitizing agent pioglitazone. Arterioscler Thromb 1993, 13:302-309.
• [15]Chen S, Li J, Zhang Z, Li W, Sun Y, Zhang Q, Feng X, Zhu W: Effects of resveratrol on the amelioration of insulin resistance in KKAy mice. Can J Physiol Pharmacol 2012, 90:237-242.
• [16]Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J: Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122.
• [17]Zhang X, Cao J, Jiang L, Zhong L: Suppressive effects of hydroxytyrosol on oxidative stress and nuclear Factor-kappaB activation in THP-1 cells. Biol Pharm Bull 2009, 32:578-582.
• [18]Yu F, Takahashi T, Moriya J, Kawaura K, Yamakawa J, Kusaka K, Itoh T, Sumino H, Morimoto S, Kanda T: Angiotensin-II receptor antagonist alleviates non-alcoholic fatty liver in KKAy obese mice with type 2 diabetes. J Int Med Res 2006, 34:297-302.
• [19]Shakibaei M, Harikumar KB, Aggarwal BB: Resveratrol addiction: to die or not to die. Mol Nutr Food Res 2009, 53:115-128.
• [20]Fromenty B, Robin MA, Igoudjil A, Mansouri A, Pessayre D: The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab 2004, 30:121-138.
• [21]Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K: In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002, 37:56-62.
• [22]Aronis A, Madar Z, Tirosh O: Mechanism underlying oxidative stress-mediated lipotoxicity: exposure of J774.2 macrophages to triacylglycerols facilitates mitochondrial reactive oxygen species production and cellular necrosis. Free Radic Biol Med 2005, 38:1221-1230.
• [23]Dobrian AD, Schriver SD, Khraibi AA, Prewitt RL: Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 2004, 43:48-56.
• [24]Saltiel AR, Kahn CR: Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001, 414:799-806.
• [25]Yen GC, Duh PD, Lin CW: Effects of resveratrol and 4-hexylresorcinol on hydrogen peroxide-induced oxidative DNA damage in human lymphocytes. Free Radic Res 2003, 37:509-514.
• [26]Haemmerle G, Lass A, Zimmermann R, Gorkiewicz G, Meyer C, Rozman J, Heldmaier G, Maier R, Theussl C, Eder S, Kratky D, Wagner EF, Klingenspor M, Hoefler G, Zechner R: Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science 2006, 312:734-737.
• [27]Turpin SM, Hoy AJ, Brown RD, Rudaz CG, Honeyman J, Matzaris M, Watt MJ: Adipose triacylglycerol lipase is a major regulator of hepatic lipid metabolism but not insulin sensitivity in mice. Diabetologia 2011, 54:146-156.
• [28]Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA: Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425:191-196.
• [29]Beher D, Wu J, Cumine S, Kim KW, Lu SC, Atangan L, Wang M: Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 2009, 74:619-624.
• [30]Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, Riera TV, Lee JE ESY, Lamming DW, Pentelute BL, Schuman ER, Stevens LA, Ling AJ, Armour SM, Michan S, Zhao H, Jiang Y, Sweitzer SM, Blum CA, Disch JS, Ng PY, Howitz KT, Rolo AP, Hamuro Y, Moss J, Perni RB, Ellis JL, Vlasuk GP, Sinclair DA: Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 2013, 339:1216-1219.
• [31]Cakir I, Perello M, Lansari O, Messier NJ, Vaslet CA, Nillni EA: Hypothalamic Sirt1 regulates food intake in a rodent model system. PLoS One 2009, 4:e8322.
• [32]de Kreutzenberg SV, Ceolotto G, Papparella I, Bortoluzzi A, Semplicini A, Dalla Man C, Cobelli C, Fadini GP, Avogaro A: Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms. Diabetes 2010, 59:1006-1015.
• [33]Barthel A, Schmoll D, Unterman TG: FoxO proteins in insulin action and metabolism. Trends Endocrinol Metab 2005, 16:183-189.
• [34]Plas DR, Thompson CB: Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J Biol Chem 2003, 278:12361-12366.
• [35]Johnson LN, Noble ME, Owen DJ: Active and inactive protein kinases: structural basis for regulation. Cell 1996, 85:149-158.
• [36]Schimmack G, Defronzo RA, Musi N: AMP-activated protein kinase: role in metabolism and therapeutic implications. Diabetes Obes Metab 2006, 8:591-602.
• [37]Ruderman N, Prentki M: AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov 2004, 3:340-351.
• [38]Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, Ke H, Rehmann H, Taussig R, Brown AL, Kim MK, Beaven MA, Burgin AB, Manganiello V, Chung JH: Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012, 148:421-433.